A new treatment for Parkinson’s?

Devin Nieusma
Share:
The Big Picture
Explore and monitor how Neuroscience is affecting economies, industries and global issues
A hand holding a looking glass by a lake
Crowdsource Innovation
Get involved with our crowdsourced digital platform to deliver impact at scale
Stay up to date:

Future of Global Health and Healthcare

This article is published in collaboration with Duke.

As if a Nobel Prize weren’t enough, another Duke scientist recently earned a prestigious award for groundbreaking research. Warren Grill was recognized Nov. 2 at the MDB Trent Semans Center for his research and development of deep brain stimulation (DBS) treatments for Parkinson’s disease.

He won the Javits Neuroscience Investigator Award, which was was created by the U.S. Congress in honor of Senator Jacob Javits, a U.S. politician who succumbed to ALS. The award is worth $4 million, and is used to fund four years of research devoted to curing neurological diseases.

In a talk recognizing his Javits award, Grill stressed the importance of developing non-pharmaceutical treatments for neurological conditions as society faces the increasing prevalence of cognitive diseases in coming decades. “Pills will not save us,” he said.Grill is a professor of biomedical engineering, neurobiology, and electrical and computer engineering at Duke whose research has earned him numerous previous awards; including the Scholar/Teacher of the Year award in 2014.

He also pointed out that pharmaceutical companies seem to avoid developing medicines for mental illness, due to their calculation that the financial cost isn’t worth the low chance of success in curing brain diseases. However, he argues, treatments such as DBS are proving them wrong.

Deep brain stimulation is the placement of a “brain pacemaker” into what is roughly the geographic center of the head, in areas such as the VIM thalamus, globus pallidus, and subthalamic nucleus. For twenty-four hours a day, every day of the year, the brain receives constant stimulation by these electrodes, causing symptoms in Parkinson’s such as tremors, rigidity, and difficulty walking to subside or even disappear. While Grill conceded that scientists do not yet understand how and why these electrodes work, he showed video evidence of patients’ improvement after receiving the treatment. For example, a patient who had a debilitating case of Parkinson’s that left him in a wheelchair was soon able to walk, make sandwiches, and even shovel snow after the implantation of the device.

Grill and his team have worked on improving the efficiency of the DBS device, giving it a longer lifespan and reducing the amount of surgical procedures that patients have to undergo (and the cost of  treatments). Whereas before, the devices would produce high-frequency stimulation to the brain to alleviate symptoms, Grill researched and developed a pattern of DBS with a lower frequency, using computational evolution, that would allow the device to work just as effectively while being up to 75% more efficient. His improvements on the device have allowed them to work up to seven years longer than before, reducing patient surgeries, and thus the risk of infection and misprogramming.

The next steps Grill expects to work on include the development of patient-specific patterns that work more effectively with individual patient’s brains. In addition, he hopes to allow patients to be able to adjust the frequency of their brain stimulation, thus allowing them the choice between efficacy and efficiency of the device throughout their daily lives. Studies are also being conducted into the use of DBS to treat other diseases such as Alzheimer’s, depression, Tourette’s, and epilepsy.

Publication does not imply endorsement of views by the World Economic Forum.

To keep up with the Agenda subscribe to our weekly newsletter.

Author: Devin Nieusma writes for Duke. 

Image: A nurse poses for a photo in a trauma center of the University of Mississippi Medical Center in Jackson, Mississippi. REUTERS/Jonathan Bachman

Don't miss any update on this topic

Create a free account and access your personalized content collection with our latest publications and analyses.

Sign up for free

License and Republishing

World Economic Forum articles may be republished in accordance with the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International Public License, and in accordance with our Terms of Use.

The views expressed in this article are those of the author alone and not the World Economic Forum.

Share:
World Economic Forum logo
Global Agenda

The Agenda Weekly

A weekly update of the most important issues driving the global agenda

Subscribe today

You can unsubscribe at any time using the link in our emails. For more details, review our privacy policy.

About Us

Events

Media

Partners & Members

  • Join Us

Language Editions

Privacy Policy & Terms of Service

© 2024 World Economic Forum